Once complete, Project Banksia, will deliver a state-of-the-art facility that will use innovative cell-based technology to produce influenza vaccines for use in both influenza pandemics and seasonal vaccination programs. The new facility will also produce unique products important to Australia’s public health needs – including antivenom for Australian snakes, spiders and marine creatures, and the world’s only human vaccine for Q-Fever.
This will be the only cell-based influenza vaccine manufacturing facility in the Southern Hemisphere.
The Lycopodium scope comprises process design, equipment specification / selection, functional specification documentation development, P&ID development, 3D modelling of equipment, valving, piping, instrumentation, generation of isometrics for construction of the process facility, electrical design of MCC, PCC’s, electrical architecture, drafting loops and single lines diagrams. Lycopodium’s scope of detailed design is due for completion in September 2022. A select team of Lycopodium employees will be seconded to assist CSL Seqirus in the construction management and commissioning of the facility.
